Kineta resumes VISTA-101 clinical trial of KVA12123

Seattle, USA-based clinical-stage biotech Kineta (Nasdaq: KA) today revealed that enrollment has resumed for the company’s ongoing VISTA-101 Phase I/II clinical trial, effective immediately.

As previously announced on March 12, 2024, patient enrollment in the clinical trial was suspended due to certain investors indicating that they would not fulfil their funding obligation due in April 2024 pursuant to the previously disclosed private placement financing.

To date, KVA12123 has cleared the fifth of six monotherapy dose levels and two of the four cohorts in combination with pembrolizumab. Initial results demonstrating partial response and stable disease in the combination cohorts and durable stable disease in the monotherapy cohorts were reported earlier this year at the American Association of Cancer Research (AACR) Annual Meeting 2024. Additionally, the initial results of KVA12123 showed a favorable clinical safety and tolerability profile with no dose limiting toxicities and no evidence of CRS-associated cytokines at any dose level.